Jun-04-18 Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts
May-29-18 Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine
May-24-18 Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology
Apr-30-18 Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
Apr-26-18 Antibe Therapeutics Announces CEO Letter to Shareholders
Apr-11-18 Antibe Therapeutics Engages Blaise Group International for Executive Search
Apr-03-18 Antibe Therapeutics Provides Financial Update
Mar-20-18 Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
Mar-13-18 Antibe Therapeutics Announces No Material Change
Feb-27-18 Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results
Feb-26-18 Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346
Jan-29-18 Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346
Jan-17-18 Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346
Nov-28-17 Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update
Oct-26-17 Antibe Therapeutics Announces Key US Distribution Partnership for its Subsidiary, Citagenix
Oct-20-17 Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions
Sep-09-17 Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug, ATB-346
Aug-29-17 Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results
Aug-18-17 Antibe Therapeutics Announces Closing of Public Offering
Aug-02-17 Antibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial